Drugs / VXB-221
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07295028 | Nov 2025 → Apr 2026 overdue | lower respiratory tract disorder | Sanofi | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VXB-221 | “VXB-221 medium dose, single, IM injection.” NCT07295028 ↗ |
| Route | Intramuscular | “VXB-221 medium dose, single, IM injection.” NCT07295028 ↗ |